Lung Cancer

NTRK1 (1q21-q22) encodes the TRKA protein, which leads to abnormal cell proliferation when rearrangement occurs;

Trk inhibitors and crizotinib reduce fusion protein phosphorylation and inhibit cell proliferation;

The first TRK inhibitor (larotrectinib) was approved by the FDA for marketing in 2018, and targets the NTRK tyrosine kinase region. ntrk is a gene encoding the trk. There are three family members, NTRK1, NTRK2, and NTRK3.NTRK gene translocation is the target of larotrectinib dosing.

Other solid tumors

NTRK1 disruption can also occur in Spitznevi (15%-20%) and is associated with NTRK1-targeted drug therapy. It is also seen in locally aggressive lipofibromatosis-like nerve tumors.